With estimates that at least 500 million people worldwide suffer from chronic kidney disease, InterWell Health, Fresenius Health Partners, and Cricket Health are merging to create a new standard in value-based kidney care in the U.S.
Formed in 2019 as a partnership with nephrologists dedicated to driving value and innovation for chronic kidney disease patients in the U.S., InterWell Health has helped improve care models for patients in ways that improve patient outcomes and achieve payor goals. With its network of more than 1,600 nephrology providers, InterWell Health is positioned to manage kidney patients under at-risk arrangements with public and private payors across the full continuum of chronic kidney disease, transplant, end stage kidney disease, and conservative care. Today marks another important step in our journey to transform kidney care and improve patients’ quality of life.
The new company will operate as an independent entity, with a separate board of directors, and a mission of expanding and improving kidney care with leading capabilities, including strong physician leadership and innovative technology to support patients across the continuum of kidney care. It will retain the InterWell Health name.
More importantly, we will keep our commitment to patient-centric values. The new InterWell Health will better harmonize workflows across the healthcare ecosystem and will ensure physicians continue to have a voice in the decisions that impact patients, physician practices, and payors.
The new entity will expand the support physicians need to elevate the way they practice medicine. By closely aligning workflows and providing the data, education, and care management resources necessary to succeed in a value based care world, the new company will work with practices to develop and implement care models specific to their community, as well as helping them contract with national payors.
The new InterWell Health will benefit from the integration of Cricket Health’s StageSmart™ machine learning and predictive glomerular filtration rate (GFR) model, pGFR™. This technology will enable the combined entity to identify and risk-stratify patients prior to kidney failure with 96% accuracy, helping slow disease progression and giving patients the time to select a treatment option that is right for them. We are confident that, with our partners, the new InterWell Health will be able to grow its operations across the U.S., providing patients with a deeply immersive and personalized experience from their care teams.
Visit TransformingKidneyCare.com for more information on the new InterWell Health. We are excited and energized by the journey ahead as we take one step closer in bringing comprehensive care to people with chronic kidney disease.
Interwell Health is a national, physician-centric joint venture between 1,100 physician investors and Fresenius Medical Care North America (FMCNA). Through its nephrology network of more than 1,600 physicians, InterWell Health is positioned to manage kidney patients under at-risk arrangements with public and private payors across the full continuum of chronic kidney disease, transplant, end stage kidney disease, and conservative care. The combined resources and clinical and analytical expertise of the nephrology partners and FMCNA are transforming care models for chronic kidney disease patients in ways that improve patient outcomes and achieve payor goals. For more information, visit the company’s website at interwellhealth.com.
SOURCE: Interwell Health